NEURACAP
M&A UpdateUpdated · 7 pages · Free to read

Medical Devices M&A update, 14–28 September 2026

This bi-weekly update tracks Medical Devices market movers, company news and M&A activity for September 14–28, 2026, across 30 covered names. Built for operators, acquirers and advisers who need a fast, sourced read on what changed, who moved, what transacted, and what it means.

For information only. Not an appraisal or a fairness opinion.

The deeper read: Medical Devices Sector Outlook — September 2026

Key figures

Covered universe median move
-0.4%
30 names, close-to-close
S&P 500 return
+0.8%
same window
PROCEPT BioRobotics (PRCT) move
-17.9%
period move
Precedent deal median EV/EBITDA
8.3x
40 recorded transactions

Read the report

NeuraCap

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL DEVICES

Evidence and Integration Earn the Bid; Legal Overhang Takes It Back

This update covers Medical Devices over September 14–28, 2026: the period's movers, company news and the one transaction the parties agreed during the window.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

1

1 / 7

Executive summary

Over September 14–28, 2026, 17 of 30 covered Medical Devices names fell against a +0.8% S&P 500, with the median move at -0.4%. Clinical evidence and integration agreements lifted Intuitive Surgical, Inc. (ISRG) +9.8% and Senseonics Holdings, Inc. (SENS) +11.3%, while litigation overhang drove PROCEPT BioRobotics Corporation (PRCT) down -17.9%. The period's sole agreed transaction, Haemonetics Corporation (HAE), left the trailing 40-deal record and its 8.3x median EV/EBITDA unchanged.

Key findings

  • 17 of 30 covered names fell; median move was -0.4%, trailing the S&P 500's +0.8%
  • Clinical evidence and integration deals drove the period's strongest gains
  • Litigation overhang hit procedure-led names hardest, led by PROCEPT BioRobotics (PRCT)
  • One agreed transaction (Haemonetics) left the 40-deal, 8.3x EV/EBITDA record unchanged

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL DEVICES

    This cover page introduces the September 14–28, 2026 bi-weekly update on the Medical Devices sector.

    This bi-weekly update covers Medical Devices from September 14–28, 2026, tracking what changed, who moved, what transacted, and what it means. We'll walk through the period's market movers, the major catalysts, and the one transaction the parties agreed during the window.

    Everything on this page

    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL DEVICES Evidence and Integration Earn the Bid; Legal Overhang Takes It Back This update covers Medical Devices over September 14–28, 2026: the period's movers, company news and the one transaction the parties agreed during the window. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    THE BI-WEEKLY BOTTOM LINE

    Clinical Evidence and Recurring-Revenue Partnerships Set the Winners

    This page summarizes the two-week period across 30 covered names, from price moves to the one transaction.

    Over the two weeks, 17 of the 30 covered names fell, with the median move at -0.4% against the S&P 500's +0.8%, so the sector lagged the broad market. The spread was wide, from RxSight, Inc. (RXST) at -23.6% to Avita Medical Inc. (RCEL) at +14.5%, and the upside was earned by clinical data and an integration deal, with Intuitive Surgical, Inc. (ISRG) up +9.8% and Senseonics Holdings, Inc. (SENS) up +11.3%. Litigation overhang priced hardest at PROCEPT BioRobotics Corporation (PRCT), down -17.9%. The period's one agreed transaction, Haemonetics Corporation (HAE), left the trailing 40-deal record and its 8.3x median EV/EBITDA unchanged — so the standing valuation frame still holds.

    Everything on this page

    THE BI-WEEKLY BOTTOM LINE Clinical Evidence and Recurring-Revenue Partnerships Set the Winners The two-week period in one page · 30 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 17 of 30 Covered Names Fell; The Median Move Was -0.4% The median covered name slipped -0.4% while the S&P 500 returned +0.8%, so the group lagged the broad market over the two-week period. The spread inside the set was wide, from RxSight, Inc. (RXST) at -23.6% to Avita Medical Inc. (RCEL) at +14.5%. 2 Clinical Data and an Integration Deal Carried the Upside Intuitive Surgical, Inc. (ISRG) gained +9.8% over the period following a da Vinci meta-analysis reported on Sep 15. Senseonics Holdings, Inc. (SENS) rose +11.3% after announcing an agreement to integrate Eversense 365 with an automated insulin delivery system. 3 Litigation Overhang Priced Hardest at the Procedure-Led End PROCEPT BioRobotics Corporation (PRCT) fell -17.9%, including -8.2% on Sep 15, with securities class action notices dated Sep 14 the visible in-window record. The complaint described in those notices centres on how consumable demand was recognised. 4 One Agreed Transaction; The Standing Valuation Frame Holds Haemonetics Corporation (HAE) was named in the period's one agreed transaction, and no completed precedent transactions were added to the record. The trailing record of 40 transactions carries a median EV/EBITDA of 8.3x, and the standing sector median of 3.4x forward revenue frames the split the period's moves followed. +14.5% Best mover — Avita Medical Inc. (RCEL) worst: RXST -23.6% · 13 up / 17 down of 30 covered -0.4% Sector median two-week return vs S&P 500 +0.8% 1 Transaction agreed in the two-week period from company announcements; not yet in the precedent record 1 Company filings in the window 8-K events read for driver attribution

  3. 03
    PUBLIC MARKET MOVERS

    Evidence and Integration Deals Earned the Bid; Legal Overhang Took the Toll

    This page charts the period's individual stock moves against the sector median and the S&P 500 benchmark.

    Bi-Weekly moves ran close-to-close from September 14–28, 2026, with the sector median at -0.4% against the S&P 500's +0.8%, and our materiality bar set at 5.8% on a sector-relative basis. Intuitive Surgical, Inc. (ISRG) gained +9.8% on a da Vinci meta-analysis, and Senseonics Holdings, Inc. (SENS) rose +11.3% on its Eversense 365 integration agreement, so evidence and partnership news earned the bid. PROCEPT BioRobotics Corporation (PRCT) fell -17.9%, including -8.2% on Sep 15, as securities class action notices became the visible driver — so litigation overhang set the discount at the procedure-led end. We attribute each move only to what filings and headlines recorded in the window.

    Everything on this page

    PUBLIC MARKET MOVERS Evidence and Integration Deals Earned the Bid; Legal Overhang Took the Toll Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -0.4% · S&P 500 +0.8% · materiality bar ±5.8% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -0.4% PROCEPT BioRobotics Corporation (PRCT) -17.9% Shares fell -17.9%, including -8.2% on Sep 15, following the Sep 14 securities class action notices. Litigation over how consumable demand was booked strikes at the razor-and-blade case itself. COMPANY-SPECIFIC Avita Medical Inc. (RCEL) +14.5% Shares rose +14.5%, with a +7.4% session on Sep 17, following the company's Sep 16 presentation at the Morgan Stanley 24th Annual Global Healthcare Conference. The available evidence suggests that update was the most visible in-window item. Core-tier ramp stories still reprice on what management says in public about adoption. COMPANY-SPECIFIC Embecta Corp. (EMBC) +13.2% No notable in-window news was identified that clearly explains the move. The +13.2% return sat well above the -0.4% median for covered names. Discount-tier names move sharply on modest flow; the rerating case still runs through recurring mix. UNEXPLAINED Senseonics Holdings, Inc. (SENS) +11.3% Shares moved following the Sep 14 announcement of a partnership to integrate Eversense 365 with an automated insulin delivery system; the partner confirmed the agreement on Sep 22. The best session was +4.1% on Sep 17. Integration agreements widen an installed base without paying to build a new channel. COMPANY-SPECIFIC

  4. 04
    MAJOR NEWS & INDUSTRY CATALYSTS

    What Companies Actually Did: Automation, Integration, Evidence and a Portfolio Separation

    This page lists the two-week period's highest-impact company events, each linked to its source.

    This page walks through the period's highest-impact events — automation moves, an integration agreement, new clinical evidence, and a portfolio separation — each linked to the underlying filing or article. Intuitive Surgical, Inc. (ISRG)'s da Vinci meta-analysis and Senseonics Holdings, Inc. (SENS)'s Eversense 365 integration agreement stand out as the evidence-and-partnership stories the market rewarded. PROCEPT BioRobotics Corporation (PRCT)'s securities class action notices mark the period's clearest legal overhang. Each "why it matters" line is our read of the recorded evidence, so treat them as informed interpretation, not fact beyond the filing itself.

    Everything on this page

    MAJOR NEWS & INDUSTRY CATALYSTS What Companies Actually Did: Automation, Integration, Evidence and a Portfolio Separation The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 15 · NEWS · Business Wire Cognyte won a new contract with a long-standing national security customer in Asia-Pacific A repeat order from an existing customer is a direct read on retention and account depth. For a Discount-tier name, renewals are the evidence that revenue quality is improving. Order flow from installed customers is the cleanest revenue-quality signal in adjacent models. Sep 14 · NEWS · PRNewsWire BD deployed its Vmax 160 pharmacy robotics in a first-of-its-kind US health system installation Placing automation inside a health system extends the hospital call point beyond dispensing. Capital placements of this kind are what lock in downstream pull-through. Enabling hardware earns its multiple through what it locks in, not through systems revenue. Sep 14 · NEWS · GlobeNewsWire Senseonics agreed to integrate Eversense 365 with an automated insulin delivery system The agreement puts a year-long sensor in front of an existing pump user base. That deepens recurring revenue rather than adding another standalone device to sell. Deals that widen the installed base are worth more than launches to a Core-tier name. Sep 14 · NEWS · PRNewsWire Medtronic launched a share exchange offer to complete a planned separation of one of its groups Diversified strategics are as active pruning portfolios as they are buying. A completed separation frees capital and management attention for the franchises the company keeps. Separations keep feeding the buyer universe with mature, cash-generative product lines. Sep 15 · 8-K · SEC EDGAR Pulse Biosciences completed enrollment in its PRECISE-BTN study and reached first 12-month follow-up Evidence milestones, not product launches, are what this sector reprices around. Completed enrollment puts a clock on the data read that supports coverage, coding and payment. Pivotal data timing is the calendar item buyers and boards plan against. Sep 14 · NEWS · GlobeNewsWire PROCEPT BioRobotics faced a securities class action with a lead-plaintiff deadline inside the period The complaint centres on how consumable demand was recognised, which puts the durability of razor-and-blade economics under scrutiny across the procedure-led group. Litigation overhang is priced as a standing value detractor, not a one-off legal cost.

  5. 05
    M&A & STRATEGIC ACTIVITY

    Haemonetics' Agreed Acquisition Triggers a Milestone Payout — the Period's One Transaction

    This page details the period's sole agreed transaction and situates it against the precedent-transaction record.

    Haemonetics Corporation (HAE) was named in the period's one agreed transaction, announced by the company itself. The trailing precedent-transaction record stands at 40 recorded deals, with a median of 8.3x EV/LTM EBITDA, and no completed transactions were added to that record this period. Deal multiples are LTM at announcement where disclosed, and our read of why the deal happened is drawn from the recorded evidence, not asserted beyond it. So the standing valuation frame carries forward unchanged into the next period.

    Everything on this page

    M&A & STRATEGIC ACTIVITY Haemonetics' Agreed Acquisition Triggers a Milestone Payout — the Period's One Transaction September 14–28, 2026 · 1 agreed by company announcement · precedent transactions: 40 recorded deals · median 8.3x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 AGREED IN THE PERIOD — FROM COMPANY ANNOUNCEMENTS Sep 15 · Haemonetics Corporation (HAE) Haemonetics Corporation (HAE) acquires a device business, triggering a milestone payment to a partner in the asset The structure is the sector's standard: value paid in stages rather than in one upfront. It suggests strategics still buy early-commercial technology with the upfront calibrated to the evidence already in hand. Terms and multiples enter the precedent record once the filing is processed; the reference set alongside is unchanged. 40 Recorded precedent transactions the reference set buyers and sellers price against 8.3x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed

  6. 06
    WHAT IT MEANS

    What the Period Changes for Operators, Buyers and Advisers

    This page translates the period's evidence into observations for operators, acquirers and advisers.

    For owners and operators, the period rewarded recurring mix and attach rate — companies showing new clinical evidence or a signed integration agreement traded higher over the two weeks. For acquirers, the record stayed anchored: no completed transactions were added, and the trailing 40-deal record still carries a median of 8.3x EV/EBITDA. For advisers, the lesson is to lead with evidence and attach economics rather than the product story, since the strongest moves followed a clinical meta-analysis and an integration agreement while the sharpest declines sat with litigation over consumable-demand recognition. These are observations drawn from the recorded evidence, not recommendations.

    Everything on this page

    WHAT IT MEANS What the Period Changes for Operators, Buyers and Advisers The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 3.4x 33 companies in the study 3 valuation tiers Standing thesis: Medical Devices Split Between Diversified Platforms, Procedure-Led Franchises and Lower-Valued Adjacent Models FOR OWNERS & OPERATORS Recurring Mix and Attach Rate Were the Levers the Period Rewarded Companies in the space that showed new clinical evidence or a signed integration agreement traded higher over the two-week period. FOR ACQUIRERS One Agreed Transaction, Staged Consideration, and an Unchanged Reference Set No completed transactions were added to the record over the period; the trailing record of 40 transactions still carries a median EV/EBITDA of 8.3x. FOR ADVISORS Lead with Evidence and Attach Economics, Not with the Product Story The strongest moves followed a clinical meta-analysis and an integration agreement; the sharpest declines sat with a name carrying litigation over how consumable demand was booked.

  7. 07
    SOURCES & METHODOLOGY

    Sources, Methodology and Important Notice

    This page explains how the update is built, what each statement rests on, and where the data originates.

    Every figure in this update links back to the record it was taken from — SEC filings, consensus estimates and market prices through September 28, 2026. We use a fixed reliability order for sources, prioritizing filings and press releases over general reporting, and we do not draw on video or social platforms. This page is here so you can verify any number in the deck against its original source.

    Everything on this page

    SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 3 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T151912Z_518_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: businesswire.com · prnewswire.com · globenewswire.com · sec.gov

Sources and methodology

This update covers Medical Devices over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 30 listed companies whose core business is Medical Devices under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Anika Therapeutics, Inc. (ANIK), Alphatec Holdings, Inc. (ATEC), AxoGen, Inc. (AXGN), Azenta, Inc. (AZTA), Becton, Dickinson and Company (BDX), Boston Scientific Corporation (BSX), Cerus Corporation (CERS), Cognyte Software Ltd. (CGNT), Delcath Systems, Inc. (DCTH), Alpha Tau Medical Ltd (DRTS), Embecta Corp. (EMBC), Glaukos Corporation (GKOS), Globus Medical, Inc. (GMED), Haemonetics Corporation (HAE), Integra LifeSciences Holdings Corporation (IART), Inogen, Inc. (INGN), InMode Ltd. (INMD), Intuitive Surgical, Inc. (ISRG), Medtronic plc (MDT), Penumbra, Inc. (PEN), Pulse Biosciences, Inc. (PLSE), PROCEPT BioRobotics Corporation (PRCT), Profound Medical Corp. (PROF), Avita Medical Inc. (RCEL), ResMed Inc. (RMD), RxSight, Inc. (RXST), Senseonics Holdings, Inc. (SENS), Stevanato Group S.p.A. (STVN), TransMedics Group, Inc. (TMDX), West Pharmaceutical Services, Inc. (WST). 3 names below the floor were excluded from the statistics: LUNG, NYXH, SRTS.

Window and company universe

This update covers Medical Devices over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 30 listed companies whose core business is Medical Devices under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Anika Therapeutics, Inc. (ANIK), Alphatec Holdings, Inc. (ATEC), AxoGen, Inc. (AXGN), Azenta, Inc. (AZTA), Becton, Dickinson and Company (BDX), Boston Scientific Corporation (BSX), Cerus Corporation (CERS), Cognyte Software Ltd. (CGNT), Delcath Systems, Inc. (DCTH), Alpha Tau Medical Ltd (DRTS), Embecta Corp. (EMBC), Glaukos Corporation (GKOS), Globus Medical, Inc. (GMED), Haemonetics Corporation (HAE), Integra LifeSciences Holdings Corporation (IART), Inogen, Inc. (INGN), InMode Ltd. (INMD), Intuitive Surgical, Inc. (ISRG), Medtronic plc (MDT), Penumbra, Inc. (PEN), Pulse Biosciences, Inc. (PLSE), PROCEPT BioRobotics Corporation (PRCT), Profound Medical Corp. (PROF), Avita Medical Inc. (RCEL), ResMed Inc. (RMD), RxSight, Inc. (RXST), Senseonics Holdings, Inc. (SENS), Stevanato Group S.p.A. (STVN), TransMedics Group, Inc. (TMDX), West Pharmaceutical Services, Inc. (WST). 3 names below the floor were excluded from the statistics: LUNG, NYXH, SRTS.

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Medical Devices?

Company valuation reports run the same method against a single business — public or private.